Table 1.

Clinical, radiological, and available histological characteristics in long-term survivors with DIPG from our cohort.

Patient ID	Sex	V cranial nerve involvement	Status	Tumor size	Ring enhancement	Treatment	Histological diagnosis	Age at diagnosis	Progression	Time to progression	Dissemination at follow up	Overall survival
8	F	Yes	DOD	2,035	No	B	Low grade astrocytoma, H3K27 wild type	104	Yes	7	Yes	32
15	M	No	DOD	1,564	No	B	Diffuse midline glioma, H3K27 mutant	79	Yes	9	No	27
16	M	No	AWD	2,070	Yes	B	Pilocytic astrocytoma	24	Yes	63	No	68
24	M	No	AWD	2,296	No	A	Not available	45	No	183	No	183
26	F	No	DOD	1,692	No	B	Diffuse midline glioma, H3K27 mutant	46	Yes	13	No	25
28	M	No	DOD	1,800	No	A	Not available	42	Yes	6	No	31

ID, patient number; sex, male (M) or female (F); V cranial nerve involvement, direct V cranial nerve involvement at diagnosis present (yes) or absent (no); Status, patient outcome including alive with disease (AWD), dead of disease (DOD) or lost at follow-up (LAF); Tumor size, tumor size expressed in mm²; Ring enhancement, ring enhancement present (yes) or absent (no) at diagnosis; Treatment, patient first line of treatment with radiotherapy and Temozolomide (A) or with radiotherapy, Nimotuzumab and Vinorelbine (B); Histological diagnosis, available histological diagnosis, according to the WHO 2016 classification; Age at diagnosis, age at diagnosis expressed in months; Progression, the presence (yes) or absence (no) of clinical and/or radiological signs of disease progression; Time to progression, the length of time from the date of diagnosis of DIPG until the radiological and/or clinical progression of the disease, expressed in months; Dissemination at follow-up, distant localization of the tumor present (yes) or absent (no) on the follow-up scans; Overall survival, overall survival expressed in months.